Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Charité coverage

This article was originally published in The Gray Sheet

Executive Summary

Cigna is the latest major payer to cover Johnson & Johnson/DePuy Spine's Charité artificial lumbar disc, the firm announces July 25. Cigna, which provides health insurance to 47 million people, joins Kaiser Permanente and Aetna, among others, who cover use of the device to treat degenerative disc disease. CMS and other payers' hesitance to cover the device, particularly due to lack of long-term follow-up data, has slowed acceptance of the procedure in the United States (1"The Gray Sheet" June 4, 2007, p. 5). DePuy says five-year Charité data is expected to be published this year...

You may also be interested in...



CMS Extends Non-Coverage Policy To All Artificial Lumbar Discs

CMS is proposing to extend its national non-coverage policy for Johnson & Johnson/DePuy's Charité to all current and future artificial lumbar discs

US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising

US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT025064

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel